Blog
RSS FeedPosted by Michael Wonder on 30 Apr 2024
Gefapixant for the treatment of patients with refractory or unexplained chronic cough
30 April 2024 - NICE is unable to make a recommendation on the use of gefapixant (Lyfnua) for the treatment of ...
Posted by Michael Wonder on 29 Apr 2024
Idebenone for the treatment of patients 12 years and older with visual impairment associated with Leber’s hereditary optic neuropathy
24 April 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Apr 2024
Melphalan flufenamide hydrochloride in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
25 April 2024 - NICE is unable to make a recommendation on the use of melphalan flufenamide hydrochloride (Pepaxti) in combination ...
Posted by Michael Wonder on 25 Apr 2024
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...
Posted by Michael Wonder on 24 Apr 2024
Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer
24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with cisplatin ...
Posted by Michael Wonder on 11 Apr 2024
170,000 people in England to have further treatment choice for preventing migraine attacks
11 April 2024 - In final draft guidance published today NICE has recommended atogepant, the first of a new type of ...
Posted by Michael Wonder on 10 Apr 2024
Cabozantinib maleate in combination with nivolumab for the first-line treatment of patients with advanced renal cell carcinoma
10 April 2024 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) in combination with ...
Posted by Michael Wonder on 03 Apr 2024
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent, high microsatellite instability or mismatch repair deficiency endometrial cancer
3 April 2024 - NICE has published final evidence-based recommendations on the use of dostarlimab (Jemperli) in combination with platinum-based ...
Posted by Michael Wonder on 02 Apr 2024
Vamorolone for the treatment of patients with Duchenne muscular dystrophy
28 March 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 02 Apr 2024
Relugolix–estradiol–norethisterone acetate for the treatment of patients with pain associated with endometriosis
28 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 27 Mar 2024
Satralizumab for the prevention of relapse in patients with a neuromyelitis optica spectrum disorder
27 March 2024 - NICE is unable to make a recommendation on the use of satralizumab (Enspryng) for the prevention of ...
Posted by Michael Wonder on 27 Mar 2024
Daratumumab in combination with bortezomib, cyclophosphamide and dexamethasone for the treatment of adults with newly diagnosed systemic light chain amyloidosis
27 March 2024 - NICE has published final evidence-based recommendations on the use of daratumumab (Darzalex) for the treatment of ...
Posted by Michael Wonder on 27 Mar 2024
Ritlecitinib tosylate for the treatment of people 12 years and over with alopecia areata
27 March 2024 - NICE has published final evidence-based recommendations on the use of ritlecitinib tosylate (Litfulo) for the treatment ...
Posted by Michael Wonder on 21 Mar 2024
Momelotinib dihydrochloride monohydrate for the treatment of patients with myelofibrosis-related splenomegaly or symptoms
20 March 2024 - NICE has published final evidence-based recommendations on momelotinib dihydrochloride monohydrate (Omjjara) for the treatment of aduklts ...
Posted by Michael Wonder on 13 Mar 2024
Dupilumab for the treatment of adults with moderate to severe prurigo nodularis
13 March 2024 - NICE has published final evidence-based recommendations on the use of dupilumab (Dupixent) for the treatment of ...